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idence is perhaps circumstantial, often based on animal studies, and is questioned by the perceived failure of
CD4-depleting antibodies to control relapsing MS. Therefore, it was interestingly to find that current MS-treat-
ments, believed to act via T cell inhibition, including: beta-interferons, glatiramer acetate, cytostatic agents, di-
methyl fumarate, fingolimod, cladribine, daclizumab, rituximab/ocrelizumab physically, or functionally in the
case of natalizumab, also depleted CD19+, CD27+ memory B cells. This depletion was substantial and long-
term following CD52 and CD20-depletion, and both also induced long-term inhibition of MS with few treatment
cycles, indicating induction-therapy activity. Importantly, memory B cells were augmented by B cell activating
factor (atacicept) and tumor necrosis factor (infliximab) blockade that are known to worsen MS. This creates a
unifying concept centered onmemoryB cells that is consistentwith therapeutic, histopathological and etiological
aspects of MS.
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Multiple sclerosis (MS) is the major inflammatory demyelinating
disease of the grey and white matter of the central nervous system
(CNS), leading to neurodegeneration and the accumulation of dis-
ability (Compston and Coles, 2002, 2008). It is clear that MS is a com-
plex disease influenced by a large number of immune- associated
genes, notably major histocompatibility complex class II alleles and
sex chromosomes (Compston and Coles, 2008; Sawcer et al., 2014).
However, the discordance between identical twins clearly indicates
that any genetic susceptibility is heavily influenced by environmen-
tal influences (Compston and Coles, 2008). These include: a geo-
graphical/latitude effect relating to sunlight exposure; lifestyle effects
including diet, education and smoking and an infection effect;
virtually all people with MS have been infected with Epstein Barr
Virus (EBV), which may be a key trigger in susceptibility to MS
(Compston and Coles, 2002, 2008; Giovannoni and Ebers, 2007).
Whilst pathology helps elucidate disease mechanisms (Compston
and Coles, 2002, 2008) perhaps the most informative method is via
the analysis of the response or lack of response to disease modifying
drugs (DMD), with consideration to the trial design and implemen-
tation (Baker and Amor, 2014), and the adverse responses to DMD
(Deiß et al., 2013; Marta and Giovannoni, 2012).2. Inflammatory and Neurodegenerative Disease in MS
This approach to disease mechanisms often defines a two immune-
compartmental model of MS (Fig. 1): (a) A peripheral compartment
that drives relapsing disease and is associatedwith entry ofmononucle-
ar cells and plasma proteins into the CNS and (b) an intrathecal/CNS
compartment that supports further white matter and grey matter de-
myelination and the loss of nerve circuitry that drives the neurodegen-
eration associated with progressive MS (showing deterioration without
obvious relapses) (Lublin et al., 2014), and accumulating disability
(Compston and Coles, 2002, 2008; Lublin et al., 2014). As such MS has
been viewed as both an autoimmune and neurodegenerative disease
requiring different treatments (Compston and Coles, 2002, 2008). How-
ever, these events are inter-related and occur concurrently fromdisease
onset (Giovannoni et al., 2017) and it is clear that immunomodulation/
suppression may be sufficient to control both relapsing and active pro-
gressive elements of MS (Steinman and Zamvil, 2016), whichmay slow
deterioration to systems with sufficient neural reserve (Giovannoni et
al., 2017; Steinman and Zamvil, 2016). However, pathology and re-
sponses to therapy indicate that targeting the peripheral component
without change in the central compartment, is often insufficient to con-
trol more advanced worsening MS (Fig. 1) (Compston and Coles, 2002,
2008; Giovannoni et al., 2017). Thus, optimal disease control is likely
to require neuroprotection and repair strategies in addition to
immunomodulation to the limit the accumulation of disability
(Compston and Coles, 2002, 2008; Giovannoni et al., 2017). Current
DMD, largely target the peripheral immune component with the view
of terminating focal inflammatory-relapse and/or magnetic resonance
imaging (MRI) activity (Fig. 1) (Marta and Giovannoni, 2012). Although
there is an increasing number of agents available to treat relapsing MS
(Marta and Giovannoni, 2012; Martin et al., 2016), failure of trials byFig. 1. Two immune-compartment model of multiple sclerosis. The initial trigger of the lesion
lymph node (outside-in) or (b) oligodendrocyte damage leading to liberation of antigen prote
autoreactive lymphocytes are sensitized. A. 1. Primed T and B cells are generated and travel
presented by a perivascular microglial (Mi) cell there is local activation of the infiltrating
adhesion molecules. 5. A second wave of influx of T cells, B cells and monocytes enters the
soluble products and possibly by direct killing by cytotoxic T cells (Tc). 7. Demyelinated ner
vulnerable to excitotoxic and other damage elements such as by activated microglial cells,
Current DMD prevent entry of the peripheral adaptive immune cells into the CNS. This will b
status of no evidence of disease activity. C. These events produce an innate inflammatory envir
created within the CNS. These may not responsive to peripheral immune control and may allo
lesion formation.immunosuppressive agents was a common problem, until the methods
to perform andmonitor phase II (based on accumulation of gadolinium-
enhancing (Gd+) T1 and newT2 lesions inMRI, respectively, andphase
III trials (outcomes based on relapses)were improved and implemented
(Compston and Coles, 2002, 2008; Marta and Giovannoni, 2012). For
this reason many drugs failed, as they were tested in people with ad-
vanced progressive MS who respond poorly or too slowly to immuno-
suppressive agents that control inflammatory relapsing MS (Coles et
al., 1999; Compston and Coles, 2002; Giovannoni et al., 2017). This is
best seen with hematopoietic stem cell therapy (HSCT) where treat-
ment is most effective in people with active inflammatory disease
with Gd+ lesions and clinical relapses (Atkins et al., 2016; Burt et al.,
2015). This suggests that once neurodegeneration is triggered within a
neural circuit, probably through innate immune activation, it may no
longer respond to the therapies that halt the relapses that trigger the
damage (Compston and Coles, 2002; Giovannoni et al., 2017;
Hampton et al., 2013). This neurodegenerative process is detectable
from the initial attacks (De Stefano et al., 2010; Giovannoni et al.,
2017), but clinical progressive deterioration may only become noticed
once the compensating neural reserve within affected pathways be-
come exhausted (Giovannoni et al., 2016a, 2017). This can occur early
as in primary progressive MS or following a number of attacks in sec-
ondary progressiveMS (progressiveworsening following a period of re-
lapsing attacks) (Compston and Coles, 2002; Giovannoni et al., 2016a;
Lublin et al., 2014). Importantly, this argues for early and effectively
treatment to maintain brain health (Giovannoni et al., 2016a).3. T Cell-specific Immunotherapies Have Proved Ineffective at
Blocking Relapsing MS
The question remains about the nature of the peripheral target for
immunotherapy. There is abundant evidence to suggest that MS is a
mainly CD4 Th1/Th17 T-cell mediated disease (Martin et al., 2016).
This concept is largely based on autoimmune experimental encephalo-
myelitis (EAE) studies in animals (Martin et al., 2016; Rostami and Ciric,
2013; Volpe et al., 2015). Surprisingly whilst all treatments that affect
MS can influence T cell function and T cell subset distribution (Martin
et al., 2016), clinical trial datawith specific CD4, Th1/Th17 immunother-
apies have all largely failed to exhibit more thanmarginal impact on re-
lapsingMS (Deiß et al., 2013; Segal et al., 2008; van Oosten et al., 1997).
This may argue against a significant role for CD4 T cells in the control of
MS. However, CD4-depletion studies were undertaken when HIV/AIDS
mechanisms uncovered the risks of CD4 lymphopenia, therefore dele-
tionwas targeted tomaintain CD4 T cell numbers above 250 cells/μL. Al-
though therewas some effect on relapse rate, the trials failed to show an
effect in reducing newMRI lesion formation,with about a 60–70% CD4 T
cell depletion (vanOosten et al., 1997). In the animalmodel, N85%CD4 T
cell depletion inhibits EAE and depletion of 30% exhibits essentially no
effect, whereas about a 60% depletion exhibits a marginal effect in an
optimized system (von Kutzleben et al., 2016). This therefore creates a
concern that the human studies failed to deplete sufficiently to control
disease.
Likewise, blockade of interleukin (IL)-12 and IL-23 with
ustekinumab to inhibit Th1 and Th17 did not significantly affect the
MRI lesion load in MS (Segal et al., 2008). Again, whilst blockade of IL-s is due to: (a) peripheral sensitization due to molecular mimicry or another event in the
ins or peptides that exit via the glymphatics to draining lymph nodes (inside-out) where
round the body. 2. Immune cells enter into the CNS. 3. Following recognition of a target
lymphocytes. 4. Cytokine release occurs to activate the blood brain barrier to express
CNS. 6. These cause damage to the oligodendrocyte (O) via release of antibodies, and
ves (N) have an elevated energy requirement to maintain neurotransmission. These are
and B cell products. 8. Microglial and B cells are sequestered into CNS compartment. B.
lock relapsing disease allowing natural repair mechanisms to act and induce a long-term
onment formed from glial cells and adaptive immune niches, such as B cell infiltrates are
w neurodegeneration and accumulation of disability to continue in the absence of active
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Fig. 2. Potential B cell functions in multiple sclerosis. B cells can exhibit a variety of
different functions (bold) that may influence MS, both in the periphery and in the CNS
where follicle-like structures accumulate during MS.
44 D. Baker et al. / EBioMedicine 16 (2017) 41–5012/23-P40 inhibits the induction of EAE, it fails to inhibit spontaneous
relapses, which is more relevant to use in MS (Heremans et al., 1999).
Blockade of IL-17 in EAE usually exhibits a modest inhibitory effect
(Kap et al., 2011; Mardiguian et al., 2013) and perhaps not surprisingly
blockade of IL-17 with secukinumab only inhibited new MRI lesions by
49% and Gd+ lesions by 67% compared to placebo from 4 to 24 weeks
(Deiß et al., 2013), which is similar or worse to that achieved with
other low-moderately effective DMD (Arnold et al., 2014). Highly effec-
tive DMD inhibit MRI lesion formation by over 85–90% (Kappos et al.,
2011). Alemtuzumab has high efficacy in active relapsing MS and de-
pletes 70–95% CD4 T cells during thewhole course of the pivotal clinical
trials (Cohen et al., 2012; Kasper et al., 2013). This suggests that, based
on response to treatments, one should not completely dismiss the pos-
sibility that MS is a T cell-mediated disease as active immunotherapeu-
tics all influence T cell activity (Martin et al., 2016). However, upon
dissection of the impact of other effective DMD, a mechanism of action
on B lymphocytes (Fig. 2) is perhaps more compelling (Fig. 2) (Disanto
et al., 2012). CD20-specific B cell depleting agents were clearly active at
inhibiting, not only new MRI lesion formation, but relapses and the ac-
cumulation of disability (Hauser et al., 2008; Kappos et al., 2011;
Sorensen et al., 2014).
4. Some MS DMD Exhibit Pleiotropic Effects, but Anti-proliferative
Drugs Preferentially Target B Cells Because of Their Enhanced Prolif-
erative Activity
Some DMD exert such pleiotropic effects that their putative mecha-
nisms of action have often followed changes in scientific dogma. As
such, their actions have been ascribed to mechanisms such as: CD8 T
suppressor cells activity, anergy, Th1 to Th2 switching, T regulatory
cell induction (Compston and Coles, 2002; Marta and Giovannoni,
2012; Martin et al., 2016). Whilst many putative mechanisms have
their origins in T cell biology (Deiß et al., 2013; Marta and Giovannoni,
2012; Martin et al., 2016), since the efficacy exhibited by CD20-specific
monoclonal antibodies (mAb) (Hauser et al., 2008; Kappos et al., 2011;
Sorensen et al., 2014), many mechanisms of action have been re-evalu-
ated in the context of B lymphocyte function (Ireland et al., 2014; Rizzo
et al., 2016; Schubert et al., 2015). Teriflunomide inhibits both prolifer-
ating T and B cells (Li et al., 2013) and the vast majority of cytostatic
agents, such as mitoxantrone and cyclophosphamide, described to tar-
get activated T cells, actually preferentially inhibit B cells, including
memory B cells (Fig. 3), by virtue of theirmore rapid proliferation kinet-
ics compared to T cells (Duddy et al., 2007; Tangye et al., 2003).
Spingosine-1-phosphate receptors, which mediate the action of
fingolimod and the alpha-4 integrin (CD49d), blocked by natalizumab,
have broad expression not only on lymphocytes but also in othermono-
nuclear cells (Marta and Giovannoni, 2012; Martin et al., 2016). Lym-
phocyte depleting agents could shed light on the mechanism of highly
active disease, but apparent confusion emerges as cladribine and
alemtuzumab deplete both T and B cells (Cohen et al., 2012; Kasper et
al., 2013; Marta and Giovannoni, 2012; Rieckmann et al., 2009), rituxi-
mab/ocrelizumab deplete primarily B cells (Hauser et al., 2008;
Kappos et al., 2011;Marta andGiovannoni, 2012),whilst daclizumab in-
hibits activated T cells and augments natural killer cell function (Kappos
et al., 2015; Marta and Giovannoni, 2012; Martin et al., 2016).
5. Inhibiting Memory B Cell Function Blocks Relapsing MS
Alemtuzumab is one of the most effective drugs and can induce
long-term no evident disease activity following a 5 then 3 day course
of 12 mg/day, one year apart (Cohen et al., 2012; Deiß et al., 2013;
Marta and Giovannoni, 2012). Based on lymphocyte effects of
alemtuzumab, T cells are most affected and CD19 B cell numbers are
normal by 6 months post-treatment (Cohen et al., 2012; Kasper et al.,
2013). However, it is evident that the CD19+ B cell response is a com-
posite of different B cell subsets (Fig. 3) and there is early and markedhyper-repopulation of immature B cells followed by a later mature B
cell response, with a continued marked depletion of CD19+, CD27+
B memory cells (Fig. 4) (Thompson et al., 2010). Consequently this
raises the questionwhether T cells ormemory B cell depletionmediated
the therapeutic effect, especially as it is reported that disease activity is
unrelated to CD4/CD8 levels (Kousin-Ezewu et al., 2014). Whilst, the
rapid repopulation of immature B cells, during a period of marked de-
pletion of absolute numbers of regulatory T cells (Cox et al., 2005;
Thompson et al., 2010), may account for the secondary B cell autoim-
munities following alemtuzumab (Cohen et al., 2012; Cox et al., 2005;
Krupica et al., 2006), inhibition of MS could relate to the depletion of
the memory B cell subsets (Fig. 4) (Thompson et al., 2010). Phenotypic
analysis from the oral cladribine studies indicated that CD4 T cells were
only depleted in the range of 40–45% and CD8 T cells were depleted by
about 15–20% from baseline, over the first year of treatment with effec-
tive doses of oral cladribine (Duddy et al., 2007; Giovannoni et al.,
2010). In contrast depletion of CD19 B cells was most marked (Duddy
et al., 2007).In the oral cladribine studies there was a clear dose-effect
between the 5.25 mg/kg and 3.5 mg/kg dose arms in terms of both
CD4 and CD8 T cell populations, but no dose-effect in relation to the
B-cell population (Duddy et al., 2007). As the 5.25 mg/kg and
3.5 mg/kg dose were equally effective (Giovannoni et al., 2010), this
would argue that the effect of cladribine is via B cell depletion.
It has been found that B cell depletion with CD20-specific mAb is ef-
fective at inhibiting relapsing MS (Hauser et al., 2008; Kappos et al.,
2011; Sorensen et al., 2014) thereby arguing against the importance of
targeting T cells to control MS. To reconcile this difference, it has been
suggested either these B cell depleting reagents block antigen presenta-
tion to T cells to limit their disease-inducing activity (Fig. 2) or that the
therapeutic antibodies target T cells (Graves et al., 2014; Martin et al.,
2016; Palanichamy et al., 2014). However, whilst CD20+ B cells are
markedly depleted following rituximab treatment, CD4 and CD8 T
cells populations are depleted only by about 10–25% in the blood
(Graves et al., 2014; Palanichamy et al., 2014; Piccio and Naismith,
2010). Unless the cells responsible for driving MS activity consist of a
very selective subpopulation, this level of depletion would be insuffi-
cient, given the fact that 60–70% depletion of CD4 T cells by CD4-deplet-
ing antibody had a marginal impact on relapses (van Oosten et al.,
1997). In contrast to the blood levels, analysis of the T and B cell levels
within the cerebrospinal fluid has reported a marked (over 50%) reduc-
tion of T cells that can occur following rituximab treatment (Piccio and
Naismith, 2010). Whilst this could be a reason for effective disease con-
trol, we feel this is more likely a consequence of effective disease con-
trol, causing both a reduction in T and B cell levels in the CNS (Piccio
and Naismith, 2010).
Fig. 3. B cell lineage and surfacemarker expression. A diagramof a simplifieddevelopment
and differentiation pathway of the B cell lineage showing some distinguishing surface
markers including ATCI (transmembrane activator and CAML interactor) protein and
BCMA (B cell maturation antigen). The memory B cell subset is heterogeneous and
includes both unswitched (CD19+, CD27+, IgM+, IgD+) and class switched (CD19+,
CD27+, IgM−, IgD−) memory B cells, which were not individually reported in some of
the studies analysed.
Fig. 4. Active DMD in MS physically or functionally deplete memory B cell activity. Depletion
(Thompson et al., 2010). The results show the depletion of the absolute numbers of memory
Science: J. Clinical Immunology. DOI: 10.1007/s10875-009-9327-3. (B) Mitoxantrone (Dudd
CD27 memory B cell before (untreated) and one month after treatment. Reproduced by pe
jimmunol.140011845. (C) Rituximab (Palanichamy et al., 2014). The results show the pe
individuals, and at different time points after rituximab (RTX). ***P b 0.0001. Reproduced by
jimmunol.140011845. (D) Fingolimod (Grützke et al., 2015). The results are individual perc
memory B cells, CD38+, CD27−, CD24+, CD5+ regulatory B cells in healthy controls (HC
treated with oral fingolimod (FTY. Blue dots). *P b 0.05. Reproduced under creative commons
results show a reduction in the individual percentage of CD19+, CD27+ B memory cells be
permission by the Nature publishing group and Macmillan Publishers Ltd.: Immunology & C
2012) induced augmentation of circulating CD19+, CD27, IgD− memory B cells. The
infusion.**P b 0.01, ***P b 0.001. Reproduced by permission from Wiley-VCH Verlag GmbH: Eu
45D. Baker et al. / EBioMedicine 16 (2017) 41–50The recommendation for a 6 monthly dosing schedule with rituxi-
mab is based on the analysis of CD19 levels that are suppressed for
6 months followed by recovery around 9–12 months after infusion
(Palanichamy et al., 2014). However, analysis of immunoglobulin non-
class switched (CD19+, CD27+, IgD+) and class-switched (CD19+,
CD27+, IgD−)memory B cell populations confirmed both of these sub-
populations are markedly suppressed for over 12 months (Fig. 4)
(Palanichamy et al., 2014). This is consistent with observation that re-
lapses were largely suppressed for at least 12 months after the last
dose of rituximab (Bar-Or et al., 2008). Furthermore, at clinical trial
doses (Kappos et al., 2011), 600 mg ocrelizumab may generate even
more marked depletion of CD19 B cells than rituximab (Genovese et
al., 2008). Sixmonthly dosingmay thus be too frequent for somepeople.
Indeed based on thephase II ocrelizumab in relapsing-remittingMS trial
extension studies (Hauser et al., 2013; Kappos et al., 2011, 2012), where
the initial placebo and interferon beta comparator groups started
ocrelizumab at 24 weeks, were treated at 24, 48 and 72 weeks and
were followed until week 144 (Hauser et al., 2013; Hughes, 2013;
Kappos et al., 2012), the relapse rate (Fig. 5) (Hughes, 2013) and pro-
gression of disability (detected in only 6/160 people in the study)
remained low for the 18 months after the last dose (Hauser et al.,
2013; Kappos et al., 2012). This indicates either a long-term depletion
effect or, more likely, an induction effectwith long term-efficacy follow-
ing only a short series of treatments, given the similarity of the putative
mechanisms of action with cladribine and alemtuzumab. Nevertheless,of CD19+, CD27+ memory B cells following treatment of MS with: (A) alemtuzumab
B cells over three treatment cycles. **P b 0.01. Reproduced by permission from Springer
y et al., 2007). The results show percentage reduction in the individual levels of CD19,
rmission American Association of Immunology: Journal of Immunology. DOI: 10.4049/
rcentage of memory B cells (CD19, CD27, IgD−) in blood before, in untreated (UNT)
permission American Association of Immunology: Journal of Immunology. DOI: 10.4049/
entage of CD38, CD27−, CD24− mature/naïve cells (black); CD38−, CD24+, CD27+
. Black dots) and people with multiple sclerosis who were untreated (MS. Red dots) or
license CC BY-NC-ND. DOI: 10.1002/acn3.155. (E) Beta interferon (Rizzo et al., 2016). The
fore (T0) and one month (T1) after weekly treatment. *****P ≤ 0.00001. Reproduced by
ell Biology. DOI: 10.1038/icb.2016.55. (Epub 2016 Jun 6). (F) Natalizumab (Planas et al.,
result show individual values at baseline and at various time after natalizumab
ropean Journal of Immunology. DOI: 10.1002/eji.201142108.
Fig. 5. Long term relapse inhibition following a short course of ocrelizumab. People with
MS were treated on day 1 and day 15 with placebo or 600 mg ocrelizumab and repeated
at week 24 as a double injection; at week 48 all participants were switched to a single
injection of 600 mg ocrelizumab that was repeated at week 72 Hauser et al., 2013. The
results represent the reported adjusted annualized relapse rate at week 48 (placebo-
controlled), week 96 (cross-over and extension) and week 144, following an 18 month
drug free period (Hughes, 2013).
46 D. Baker et al. / EBioMedicine 16 (2017) 41–50repeated dosing may be necessary to maintain control of MS relapses.
Indeed, a personalized, repeat-treatment depending on levels of circu-
latingmemory B cells rather than total CD19+ B cells may be sufficient
to control relapsing disease. This strategy has been successfully applied
to rituximab treatment of neuromyelitis optica, a demyelinating disease
associated with optic neuritis and myelitis and the presence of patho-
genic aquaporin-4-specific antibody (Kim et al., 2011).
Daclizumab blocks the high affinity interleukin-2 (IL-2) receptor
(CD25), which will inhibit T cell activation, and controls relapsing mul-
tiple sclerosis (Gold et al., 2016; Kappos et al., 2015). This was thought
to be due to the expansion of CD56high natural killer cells that express
the intermediate affinity IL-2 receptor containing the IL-2beta
(CD122) and IL-2 gamma (CD132) chains (Gold et al., 2016; Kappos et
al., 2015; Marta and Giovannoni, 2012). However, it is interesting that
10-65% of peripheral B cells can express CD25, in addition to CD122
and CD132 (Brisslert et al., 2006). Furthermore, only the memory B
cell population expresses CD25, in particular, 60% of CD19+, CD27+
B cell express CD25 and blockade of IL-2 activity can inhibit B cell activ-
ity (Brisslert et al., 2006). As such, it is evident that daclizumab not only
depletes cells in the CD4 T cell pool but also significantly affects CD19+
B cells (Lin et al., 2015; Toso et al., 2009). It is therefore possible that the
effect of daclizumabmay be via a reduction in the activity of B cellmem-
ory in MS. Indeed in the transplantation setting, daclizumab decreased
the absolute number of Bmemory cells, but consistentwith its lower ef-
ficacy, this was less than that observed with alemtuzumab (Toso et al.,
2009). In addition, whilst fingolimod is known for sequestration of cen-
tral memory T cell within lymph nodes, B cells are likewise reduced
within a fewweeks of treatment onset, with a significant decrease in ac-
tivated memory B cells (Fig. 4) (Grützke et al., 2015; Nakamura et al.,
2014). Likewise, mitoxantrone, causes a drop in the number of periph-
eralmemory B cells (Fig. 4) (Duddy et al., 2007), as does dimethyl fuma-
rate (Lundy et al., 2016). Interestingly the effect was, again, not as
marked with alemtuzumab or rituximab (Palanichamy et al., 2014;
Thompson et al., 2010) and may account for dimethyl fumarate
exhibiting a lower level of activity at inhibiting relapses andMRI lesions,
compared to CD20 and CD52 depletion via mAb (Deiß et al., 2013;
Martin et al., 2016). Teriflunomide is an anti-proliferative agent that
blocks pyrimidine synthesis by inhibition of dihydroorotate dehydroge-
nase (Marta and Giovannoni, 2012). Teriflunomide is the active metab-
olite of leflunomide, which produces a modest decrease of memory B
cells in rheumatoid arthritis (McComish et al., 2015). In contrast, whilst
natalizumab has some influence on circulating T cells andmonocytes, Bcells and notably circulating memory B cells were increased (Fig. 4)
(Planas et al., 2012). This would be consistent with blockade of alpha
4 integrin (CD49d) binding to vascular cell adhesion molecule one
(CD105) on inflamed CNS blood vessels (Marta and Giovannoni, 2012;
Martin et al., 2016) blocking entry of activated cells into the brain and
sequestering them in the periphery (Fig. 4). Whilst these current MS
treatments have complex mechanisms of action involving different leu-
kocyte subsets (Marta and Giovannoni, 2012; Martin et al., 2016), this
insight provides a unifying hypothesis that all current DMD are active
through depletion, or functional inhibition, of cells within the CD19+,
CD27+ B cell memory lineage (Table 1).
6. Augmenting B Memory Cell Function can Worsen MS
Following the apparent efficacy of CD20-depleting agents in control-
ling MS (Hauser et al., 2008; Kappos et al., 2011; Sorensen et al., 2014),
alternative methods of depleting B cells have been developed. One ap-
proach was the use of CD19 depleting antibodies (MEDI-551), which
have a broader range of B cell depletion than CD20-targeting to include
plasmablasts (Ward et al., 2011). MEDI-551 effectively blocked the for-
mation of new MRI lesions in a phase II trial (NCT01585766) in MS
(Aquis et al., 2015).
Another approachwas the neutralization of B cell growth and differ-
entiation factors which are altered in people with MS in particular dur-
ing relapses (Kannel et al., 2015). Atacicept is a fusion protein composed
by the transmembrane activator and calciummodulator and cyclophilin
ligand interactor protein (TACI) and the constant region of human IgG1
(Gatto, 2008). Atacicept neutralizes a proliferation-inducing ligand
(APRIL) and B lymphocyte stimulator (BLyS)/B cell activating Factor
(BAFF), that stimulate B cell numbers, activation and antibody synthesis
(Gatto, 2008). However, in trials to control optic neuritis, atacicept pre-
cipitated CNS inflammation and augmented the conversion of people
with optic neuritis to clinically definite MS (Sergott et al., 2015). Al-
though, the effect on B cell subsets in this trial was not reported
(Sergott et al., 2015), it is evident from other studies in humans and
mice that whilst atacicept results in a loss of mature B cells, it
upregulates interleukin-15 (IL-15) and stimulates memory B cells
(Table 1) (Ma et al., 2014; Tak et al., 2008). Therefore, in contrast to
memory B cell reduction and disease inhibition seen with other MS
treatments, atacicept caused disease worsening in some people with
optic neuritis, an effect probably associated with enhanced memory B
cell function. Furthermore, a trial (NCT00882999) of tabulumab
(Lys2127399), which is a human IgG4 antibody that inhibits bothmem-
brane and soluble BAFF/BLyS and augments memory B cell function
(Genovese et al., 2013), may have failed or was terminated (Deiß et
al., 2013). In addition, tumor necrosis factor (TNF) inhibitors canworsen
MS (Lenercept Multiple Sclerosis Study Group and the University of
British Columbia MS/MRI Analysis Group, 1999; van Oosten et al.,
1996). Interestingly, TNF inhibition is associated with augmentation of
memory B cells numbers, when used in some people with rheumatoid
arthritis or Crohn's disease, who sometimes develop central nervous
system demyelinating disease after TNF inhibition (Hyrich et al., 2004;
Roll et al., 2012; Souto-Carneiro et al., 2009). In conclusion, evidence
shows that drugs that reduce the CNS activity of the subset of CD19+,
CD27+ memory B cell are beneficial for MS and drugs that promote it
are not effective and can actually make MS worse or trigger the disease
(Table 1). A strategy that specifically targets thememory B cell function
but avoids the immature, mature non-memory B cell subsets may im-
prove the benefit:risk ratio (Krupica et al., 2006).
Natalizumab induced circulating memory B cell elevation (Fig. 4)
(Planas et al., 2012) is not associated with worsening of MS, whilst it
was the case for atacicept (Table 1). This is presumably becausememory
B cells are prevented from entering the CNS to trigger relapse with
natalizumab (Michel et al., 2015), but not atacicept. Alternatively
natalizumab could be disturbing critical niches within the bone marrow
and lymphoid organs and/or inhibiting an important peripheral immune
Table 1
MS treatments limit the capacity of memory B cells to enter the CNS.
MS treatment Memory B cells in the blood Availability of B cells to enter CNS Relapse rate/MRI lesions
Glatiramer acetate Reduced (Ireland et al., 2014) Decreased Decreased
Beta Interferon Reduced (Rizzo et al., 2016) Decreased Decreased
Dimethyl fumarate Reduced (Lundy et al., 2016) Decreased Decreased
Mitoxantrone Reduced (Duddy et al., 2007) Decreased Decreased
Fingolimod Reduced (Grützke et al., 2015) Decreased Decreased
Natalizumab Increased (Planas et al., 2012) Decreased Decreased
Alemtuzumab Reduced (Thompson et al., 2010) Decreased Decreased
Daclizumab Reduced (Gold et al., 2016)* Decreased Decreased
Rituximab Reduced (Palanichamy et al., 2014) Decreased Decreased
Atacicept Increased (Sergott et al., 2015)* Increased Increased
Infliximab Increased (Souto-Carneiro et al., 2009)* Increased Increased
HSCT Reduced (Burns et al., 2015)* Decreased Decreased
The known effects of various DMD on the relapse rate andMRI lesion formation inMS and their reported effects, with citation indicated, on the levels of memory cells within the blood in
MS, or other conditions where data in MS is lacking*, and the likely impact on such cells entering the CNS.
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B cells in the blood may contribute to rapid disease rebound that can
occur following cessation of natalizumab (Rasenack and Derfuss, 2016).
This would support CD20-depleting agents as the switching agent of
choice post-natalizumab to deplete the increased numbers of circulating
memory B cells (Giovannoni et al., 2016b). Indeed post-natalizumab
treatment with rituximab has been associated with lower relapse levels
than with fingolimod switching and is arguably safer than fingolimod as
it does affect cytotoxic T cells that may be required to clear subclinical
progressive multifocal leukoencephalopathy (Alping et al., 2016;
Asztely et al., 2015).
7. Mechanisms of B Cell Activity in MS
In MS, higher BAFF levels are associated with less active disease
(Kannel et al., 2015). Conversely, there is disease worsening when
BAFF is neutralized with atacicept, which will increase memory B cell
numbers (Sergott et al., 2015).Whilst B cell subpopulations fluctuate
in MS (Teniente-Serra et al., 2016), it is interesting that people with pe-
diatric MS have generated a substantial pool of memory B cells com-
pared to healthy children and adolescents (Schwarz et al., 2016). Cells
within the CD19+, CD27+ pool may decrease in the blood during re-
lapse and they accumulate within the CNS (Schwarz et al., 2016). Fur-
thermore, increased circulating memory B cell numbers were
associated with accumulation of neurodegeneration in relapsing MS
(Comabella et al., 2016) and they can be detected in MS post-mortem
lesions (Serafini et al., 2010). However, it will be important to deter-
mine how this is achieved, asmemory B cells can exhibitmany different
functions (Fig. 2) and the CD19+, CD27+B cell population is heteroge-
neous (Michel et al., 2015). It is possible that these B cells act key anti-
gen-presenting cells to drive T cells to cause the central problems of
MS; they do express co-stimulatory molecules and major histocompat-
ibility complex and can present myelin antigens (Harp et al., 2010;
Michel et al., 2015; Toso et al., 2009). As such it is of interest that soluble
CD27, produced by memory T and B cells, has been proposed as a bio-
marker of inflammation in MS and is associated with the immunoglob-
ulin index in the cerebrospinal fluid/serum (Hintzen et al., 1991;
Komori et al., 2015). Whilst this was associated with T cell activity, it
may in fact also relate to memory B cell activity within the CNS tissue
(Hintzen et al., 1991). Loss of memory cells may alter the balance in
favor of mature cells or regulatory B cells that produce IL-10 and create
amore regulatory environment (Duddy et al., 2007;Michel et al., 2015).
Alternatively these cells could be forerunner to the formation of plasma
cells responsible for the production of pathogenic intra-thecal antibod-
ies. It is clear in MS that autoantibodies exist and are part of the pathol-
ogy (Agahozo et al., 2016; Michel et al., 2015; Pedotti et al., 2013).
Pathogenic antibodies specifically target oligodendrocytes or neurons
through antigen binding via the antibody Fab regions or even throughactivation of innate immune cells via signaling through Fc receptors
(Agahozo et al., 2016;Michel et al., 2015; Pedotti et al., 2013). It appears
as if the pathogenicmemory B cells have been identified (Li et al., 2015).
They are the pro-inflammatory granulocyte macrophage-colony stimu-
lating factor producing B cells expressing: CD22, CD24, CD25, CD27,
CD49d, CD83, CD180, CD38low, HLA-DR, CCR2, CCR6 (Li et al., 2015),
which are increased in MS (9.3 ± 1.4% untreated MS verses 4.4 ±
0.5%) compared to healthy matched controls (Li et al., 2015). Further
work, will be needed to determine that this subset is indeed affected
by the different MS treatments.8. Memory B Cells in the Etiology of MS
The data strongly support that thememory B cell population is a key
component of the pathological features in MS (Table 1). Although the
etiology of MS is thought to be autoimmune, no consistent T or B cell
autoantigen has been described, even after analysis of sequences of in-
filtrating B cells (Blauth et al., 2015; van Nierop et al., 2016). Whilst T
and B cell autoimmunity is clearly present in people with MS
(Agahozo et al., 2016; Blauth et al., 2015; van Noort et al., 2010), this
may be secondary to damage rather than being the primary driver of
the disease. As such, the complement C2 receptor that is expressed by
CD27+ memory B cells is the co-receptor used by Epstein Barr Virus
(EBV) to infect and subsequently immortalize B cells (Ascherio and
Munger, 2015; Burns et al., 2015; Fernández-Menéndez et al., 2016). It
has been observed that theBAFF levels, which are elevated inMS, are re-
lated to EBV immunity that depletes, or is associatedwith a reduction in
B memory cells (Mameli et al., 2016; Panikkar et al., 2015). Further-
more, as latent EBV proteins mimic B cell receptor signaling, if the
BAFF signaling pathway is blocked thememory-EBV infected B cell pop-
ulation is likely to expand (Vrazo et al., 2012). Importantly EBV reactiva-
tion can drive the expansion of latently-infected CD19+, CD27+B cells
(Burns et al., 2015) and possibly contribute to disease worsening inMS.
Memory B cells thus form the reservoir for latent EBV infection and
therefore their destruction will remove the viral load and potential eti-
ological triggers that could precipitate relapse (Ascherio and Munger,
2015; Fernández-Menéndez et al., 2016). Furthermore most B cells in
MS lesions, meninges and ectopic B cell aggregates are CD27 antigen
positive and are the population of cells that have been shown to co-ex-
press latent EBV proteins and support a role for EBV infection in B-cell
activation in theMS brain (Serafini et al., 2010). This will need to be elu-
cidated further.
However, irrespective of the data implicating EBV-infected B cells, the
data presented here suggests memory B cells are of central importance in
for the development of MS. Developing agents that are more specific for
these CD19+, CD27+ B memory cells may improve the risk-benefit
ratio compared to current therapies,which targetmultiple subsets of cells.
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Search Strategy and Selection Criteria
The review was based on initial analysis of leukocyte phenotyping
data from clinical trials and was used to formulate the hypothesis for
the content of the review. References were then identified by searches
of Pubmed and Google.co.uk. These used the search terms relating to
the “non-proprietary drug name” and/or “class of drug type” and “mem-
ory B cell” or “CD27” with or without “multiple sclerosis”. Preference
was given to work conducted in multiple sclerosis versus other autoim-
mune diseases. The final reference list was generated on the basis of rel-
evance to the topic covered in the review.
Outstanding Questions
This review shifts focus from T cell biology towards B cell memory
function andopens a series of newquestions concerning the pathogenesis
of multiple sclerosis. How doesmemory B cell function actually drive dis-
ease? Is this via immune activity to cause direct pathology or do they
stimulate T to cause damage? Importantly, do they act as a reservoir for
the tentative etiological viral trigger of multiple sclerosis? Does the bene-
fit relate to a central action of B cells or is peripheral targeting sufficient?
What is the precise phenotype of the pathogenic cells within thememory
B cell pool? Canmonitoring of memory B cell numbers be used as a prog-
nostic feature and biomarker that allows one to personalize treatment
and retreatment? Importantly, can more specific targeting of memory B
cells be achieved to exhibit comparable benefit to more global B cell de-
pletion, whilst de-risking side effect issues of current treatments?
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